Curreus, 10/18/2026
A case report published in Cureus on October 18, 2026, describes structural and functional recovery in a patient with a complete Achilles tendon rupture and a 3.7 cm intertendinous gap. The treatment combined intravenous human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs), ultrasound-guided local administration of hUC-MSC-derived extracellular vesicles (EVs), and a phased rehabilitation program. These findings provide a preliminary clinical observation supporting further investigation of biologic approaches to tendon repair. However, controlled clinical studies are required to determine their safety and efficacy.
The challenge of Achilles tendon repair
The Achilles tendon connects the calf muscles to the heel bone and plays a central role in walking, running, and athletic activities. An acute rupture can cause severe pain, swelling, and an inability to bear weight. Surgical repair is commonly considered for complete ruptures with a substantial gap between the tendon ends, where restoration of mechanical continuity is a major clinical concern.
Tendon healing is biologically complex. Because tendons have relatively limited vascularity and specialized structural properties, healing may involve scar formation and remodeling rather than complete restoration of native tissue architecture. These processes can contribute to tendon elongation, stiffness, and recurrent injury. Although nonoperative management combined with functional rehabilitation can achieve favorable outcomes in selected patients, complete ruptures with large gaps remain challenging.
Mesenchymal stem/stromal cells (MSCs) and extracellular vesicles are being investigated as potential biologic approaches because of their capacity to modulate inflammation and influence the local tissue microenvironment.
A combined regimen of systemic hUC-MSCs and local EV administration
In their report, Nonoperative Management of an Acute Complete Achilles Tendon Rupture With Mesenchymal Stem Cells and Extracellular Vesicles: A Case Report, Ortiz and Diaz described a physically active 45-year-old man who sustained a right Achilles tendon injury while playing recreational tennis on November 17, 2024. Magnetic resonance imaging (MRI) confirmed a complete midsubstance rupture approximately 6.1 cm proximal to the calcaneal insertion, with a 3.7 cm gap between the tendon ends.
After counseling, the patient elected to pursue nonoperative management. The treatment protocol combined two biologic interventions with structured rehabilitation.
First, the patient received intravenous hUC-MSC infusions on three consecutive days, December 2–4, 2024. Each infusion contained 50 million cells, for a total dose of 150 million cells. According to the authors, this systemic intervention was intended to support immunomodulation and create a favorable environment for tissue repair.
Second, hUC-MSC-derived EVs were administered locally under ultrasound guidance on December 12 and 20, 2024. Each session involved 15 billion vesicles, for a total of 30 billion vesicles. The preparation was delivered to the rupture gap, both tendon stumps, and the surrounding peritendinous tissue to target the injured region.
The biologic interventions were accompanied by a four-phase rehabilitation program extending over approximately 12 months. Rehabilitation began with protected immobilization and progressed through controlled weight-bearing, range-of-motion exercises, strengthening, balance training, and more advanced functional activities.
Biological rationale: Immunomodulation and tissue remodeling
MSCs may influence tissue repair through paracrine signaling, releasing bioactive molecules that affect neighboring cells rather than relying solely on direct engraftment and differentiation. Some of this biological activity is conveyed by extracellular vesicles, including the exosome subpopulation, which carry proteins, lipids, and regulatory RNA.
Preclinical studies cited by the authors suggest that MSC-derived EVs may attenuate early inflammatory responses following tendon injury, influence macrophage phenotypes toward a pro-regenerative state, and promote tenocyte proliferation and migration. Other experimental findings suggest potential benefits for collagen organization and the biomechanical properties of healing tendon tissue.
Preclinical research on hUC-MSC-derived exosomes has also implicated the mTOR signaling pathway in tendon regeneration. Based on this evidence, the authors proposed that systemic hUC-MSC administration and targeted local EV delivery might provide complementary effects, while progressive rehabilitation supplies mechanical stimuli that support tissue remodeling.
These mechanisms remain biologically plausible hypotheses rather than demonstrated mechanisms in the reported patient. The case report did not directly establish the proposed molecular effects or determine the independent contribution of each treatment component.
Follow-up findings: Restoration of tendon continuity and function
Pain intensity, measured on a 0–10 numerical rating scale, decreased from 10 at baseline to 6 after two weeks, 4 after three months, and 0 at both six and 12 months.
At nine months, the Thompson test was negative, consistent with restored functional continuity of the tendon. At approximately 12–14 months, the patient achieved scores of 100/100 on both the Achilles Tendon Total Rupture Score (ATRS) and the American Orthopaedic Foot & Ankle Society (AOFAS) ankle-hindfoot scale.
Instrumented biomechanical assessment demonstrated relatively symmetrical performance between the lower limbs. However, a residual limitation in ankle dorsiflexion remained during the forward-lunge task, measuring 21° on the injured side compared with 28° on the contralateral side.
Follow-up MRI performed on February 4, 2026, demonstrated restoration of tendon continuity, with no residual gap or evidence of re-rupture. The tendon remained thickened and exhibited residual intrasubstance signal changes, which the authors interpreted as consistent with scar remodeling after healing.
At final follow-up, the patient had returned to gym training and jogging without reported pain or functional limitations. No adverse events were reported during treatment or rehabilitation.
Clinical implications and limitations
This case provides a notable clinical observation of recovery following combined hUC-MSC administration, local EV delivery, and structured rehabilitation in a complete Achilles tendon rupture with a substantial gap. Nevertheless, the report describes only one patient and includes no control group. It therefore cannot establish a causal relationship between the biologic interventions and the observed outcome.
Spontaneous healing under nonoperative management and the effects of rehabilitation are important potential confounders. The study also cannot distinguish the individual contributions of systemic hUC-MSCs and locally administered EVs. In addition, the authors stated that the biologic product used was not a licensed biologic and was administered outside a registered clinical trial. The treating institution was also the manufacturer of the biologic product used in the case, a relevant consideration when interpreting the findings.
Future prospective controlled studies are needed to evaluate safety and efficacy and to establish appropriate dosing, timing, and delivery routes. Standardized EV characterization, serial imaging, and objective functional assessments will be important for determining the contribution of each component of the treatment strategy.
Conclusion: This case report highlights the research potential of combining hUC-MSCs and EVs to support tendon repair. Although the patient achieved favorable structural and functional outcomes, the available evidence is insufficient to establish treatment efficacy or support replacing standard treatment options. Controlled clinical studies are necessary before the role of MSC- and EV-based approaches in Achilles tendon rupture management can be determined.
References
Ortiz A, Diaz C. Nonoperative Management of an Acute Complete Achilles Tendon Rupture With Mesenchymal Stem Cells and Extracellular Vesicles: A Case Report. Cureus. 2026;18(10). Published October 18, 2026. doi:10.7759/cureus.118122.
Source: Cureus
Link: https://www.cureus.com/articles/524705-nonoperative-management-of-an-acute-complete-achilles-tendon-rupture-with-mesenchymal-stem-cells-and-extracellular-vesicles-a-case-report?score_article=true#!/




